<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893526</url>
  </required_header>
  <id_info>
    <org_study_id>NEPT2D</org_study_id>
    <nct_id>NCT03893526</nct_id>
  </id_info>
  <brief_title>Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes</brief_title>
  <acronym>NEPT2D</acronym>
  <official_title>The Effect of Neprilysin on Plasma Concentrations of Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced
      insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within
      minutes and DPP-4 inhibitors are therefore used for treatment of diabetic hyperglycemia. A
      few animal studies have implicated the enzyme neutral endopeptidase 24.11 (24.11) in the
      degradation of GLP-1 but if this is the case in humans with type 2 diabetes is unknown.

      We therefore administered a NEP inhibitor, 194mg sacubitril, a DPP-4 inhibitor (sitagliptin
      100mg the night before and 100mg 2 hours before), both, or placebo, to patients with type 2
      diabetes during a standardized meal and measured plasma concentrations of GLP-1
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Glucose</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
    <description>Plasma Concentrations of glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of GLP-1</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of GIP</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Glucagon</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Insulin</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of C-Peptide</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Amino Acids</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants are subjected to a standardized meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entrestro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entrestro + sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>206mg valsartan as one single dose followed by a standardized meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entresto</intervention_name>
    <description>Single dose administration of entresto</description>
    <arm_group_label>Entrestro</arm_group_label>
    <arm_group_label>Entrestro + sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Single dose administration of sitagliptin</description>
    <arm_group_label>Entrestro + sitagliptin</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>single doses administration of valsartan</description>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes

          -  Oral Antidiabetics Medicine Only

          -  Body Mass Index of 25-35

          -  Type 2 Diabetes

        Exclusion Criteria:

          -  acute diseases within the two weeks

          -  chronic diseases

          -  smoker

          -  alcoholism, drug addiction or recent weight loss

          -  blood donation within the last 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christoffer Martinussen, MD</last_name>
    <phone>+4538626357</phone>
    <email>Christoffer.martinussen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kirstine Bojsen-Møller, MD,PhD</last_name>
    <email>kirstine.nyvold.bojsen-moeller@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>RegionH</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoffer Martinussen, MD</last_name>
      <phone>+4538626357</phone>
      <email>Christoffer.martinussen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Møller, Msc</last_name>
      <phone>+4538623032</phone>
      <email>Andreas.moeller@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Sten Madsbad, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Nicolai Jacob Wewer Albrechtsen</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>Neprilysin</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

